Drug Trial Radar · NCT01807923
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
Last checked: Nov 19, 2026Latest source record: Aug 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
559
Actual
Start
May 2013
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.
Conditions
- Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor CombinationDrug
Fixed dose combination tablet
IvacaftorDrug
Film-coated tablet
PlaceboDrug
Matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline, Week 16 and 24
Locations
89 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Anchorage, Alaska
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Fresno, California
Site not named
La Jolla, California
Site not named
Loma Linda, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Madera, California
Site not named
Oakland, California
Site not named
Palo Alto, California
Site not named
Denver, Colorado
Site not named
Gainsville, Florida
Site not named
Hollywood, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Chicago, Illinois
Site not named
Park Ridge, Illinois
Site not named
Peoria, Illinois
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Kansas City, Missouri
Site not named
Bedford, New Hampshire
Site not named
Lebanon, New Hampshire
Site not named
Long Branch, New Jersey
Site not named
Hawthorne, New York
Site not named
New York, New York
Site not named
Valhalla, New York
Site not named
Chapel Hill, North Carolina
Site not named
Durham, North Carolina
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
Dayton, Ohio
Site not named
Portland, Oregon
Site not named
Hershey, Pennsylvania
Site not named
Knoxville, Tennessee
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.